Research programme: aerosol delivered therapeutics - Alulim

Drug Profile

Research programme: aerosol delivered therapeutics - Alulim

Alternative Names: Alpha-TEA - Alulim; cyclosporin A - Alulim; cyclosporine A - Alulim

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alulim Pharma
  • Class Acetic acids; Ciclosporins; Small molecules; Tocopherols
  • Mechanism of Action Calcineurin inhibitors; Fatty acid inhibitors; Free radical inhibitors; Immunosuppressants; Membrane lipid modulators; Mitochondrial permeability transition pore inhibitors; P-glycoprotein inhibitors; Tumour suppressor protein p53 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Asthma; Cancer; Chronic obstructive pulmonary disease; Transplant rejection

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Asthma in Brazil (Inhalation, Liposomal)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Asthma in China (Inhalation, Liposomal)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Asthma in USA (Inhalation, Liposomal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top